Top Markets
#1 Seeker Seeker +134.80%
#2 AI XOVIA AI XOVIA +105.87%
#3 MowCat MowCat +70.14%
#4 Helium Helium +65.13%
#5 Cortex Cortex +62.84%
#6 Pons Pons +37.19%
#7 UnifAI Network UnifAI Network +32.97%
#8 Zora Zora +27.86%
#9 Zylo Ecosystem Zylo Ecosystem +20.74%
#10 Bounce Bounce +16.77%
Coin of the day
Seeker Seeker
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Nxera Pharma Co., Ltd. Nxera Pharma Co., Ltd.

Nxera Pharma Co., Ltd.

4565
Classifica tra le azioni #11674
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a... Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
Prezzo delle azioni
$7.32
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$671.50M
Variazione (1 giorno)
1.08%
Variazione (1 anno)
16.38%
Paese
JP
Scambia Nxera Pharma Co., Ltd. (4565)

Categoria

Healthcare
Ricavi di Nxera Pharma Co., Ltd. (4565)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Nxera Pharma Co., Ltd., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Nxera Pharma Co., Ltd. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH